Compositions comprising an aryl pyrazole and a substituted imidazole, methods and uses thereof

Patent metadata

Field	Value
Publication number	US-9173404-B2
Application number	US-201214358309-A
Country	US
Kind code	B2
Filing date	Nov 16, 2012
Priority date	Nov 17, 2011
Publication date	Nov 3, 2015
Grant date	Nov 3, 2015

Abstract

This invention relates to compositions for combating parasites in animals, comprising 1-arylpyrazole compounds in combination with substituted imidazole compounds. This invention also provides for an improved methods for eradicating, controlling, and preventing parasite infestation in an animal comprising administering the compositions of the invention to an animal in need thereof.

First claim

What is claimed is:

1. A veterinary formulation for treating or preventing a parasitic infestation in an animal comprising:
(a) a 1-aryl-5-alkyl or 5-haloalkylpyrazole of formula (IA) or aveterinarily acceptable salt thereof,

wherein:
R 2a is —S(O) m R 11a ;
R 3a is methyl, ethyl or C 1 -C 4 haloalkyl;
R 4a is halogen;
R 6a is C 1 -C 4 alkyl or haloalkyl;
R 13a is halogen;
R 11a is C 1 -C 4 haloalkyl; and
m is 0, 1 or 2;

(b) a substituted imidazole compound of formula (II),

wherein
X 1 is H, Cl, or CH 3 ;
X 2 and X 8 are H;
X 3 is H, F, —OCH 3 , Cl, I, —OCHF 3 , —OCF 3 , NH 2 , CHCH 2 , CHCHCH 3 , CCH, CCCH 3 , C 2 H 5 or CH 3 ;
X 4 , X 5 , X 6 and X 7 are H or CH 3 ;
(c) a veterinarily acceptable carrier; and
(d) optionally a crystallization inhibitor.

2. A veterinary formulation for treating or preventing a parasitic infestation in an animal comprising:
(a) a 1-aryl-5-alkyl or 5-haloalkylpyrazole of formula (IB) or a veterinarily acceptable salt thereof,

wherein:
R 1b is alkyl, CN or halogen;
R 2b is S(O) 6 R 14b or 4,5-dicyanoimidazol-2-yl or haloalkyl;
R 14b is alkyl or haloalkyl;
R 3b is a hydrogen, halogen, —NR 7b R 8b , —S(O) m R 9b , —C(O)R 9b , —C(O)OR 9b , alkyl, haloalkyl, —OR 10b or an —N═C(R 11b ) (R 12b );
R 6b is a halogen, haloalkyl, haloalkoxy, S(O) q CF 3 or SF 5 group;
R 7B and R 8B independently represent a hydrogen, alkyl, haloalkyl, —C(O)alkyl, —S(O) r CF 3 , acyl or alkoxycarbonyl; or
R 7b and R 8b can together form a divalent alkylene radical which is optionally interrupted by one or two divalent heteroatoms;
R 9b is an alkyl or haloalkyl;
R 10b is hydrogen, alkyl or haloalkyl;
R 11b is hydrogen or alkyl radical;
R 12b is an optionally substituted aryl or an optionally substituted heteroaryl group;
R 4b and R 13b represent, independently of one another, hydrogen, halogen CN or NO 2 ;
m, n, q and r represent, independently of one another, an integer equal to 0, 1 or 2; and
Z represents a trivalent nitrogen atom or a C—R 13b radical, the three other valencies of the Carbon atom forming part of the aromatic ring;
(b) a substituted imidazole compound of formula (II),

wherein
X 1 is H, Cl, or CH 3 ;
X 2 and X 8 are H;
X 3 is H, F, —OCH 3 , Cl, I, —OCHF 3 , —OCF 3 , NH 2 , CHCH 2 , CHCHCH 3 , CCH, CCCH 3 , C 2 H 5 or CH 3 ;
X 4 , X 5 , X 6 and X 7 are H or CH 3 ;
(c) a veterinarily acceptable carrier; and
(d) optionally a crystallization inhibitor.

3. The composition of claim 2 , wherein:
R 1b is methyl, CN or halogen;
R 2b is S(O) 6 R 14b ;
R 14b is C 1 -C 6 -alkyl or C 1 -C 6 -haloalkyl;
R 3b is —NR 7b R 8b ,
R 7b and R 8b independently represent a hydrogen, C 1 -C 6 -alkyl, C 1 -C 6 -haloalkyl, —C(O)C 1 -C 6 -alkyl, —S(O) r CF 3 , C 1 -C 6 -acyl or C 1 -C 6 -alkoxycarbonyl radical;
R 6b is a halogen, C 1 -C 6 -haloalkyl, or C 1 -C 6 -haloalkoxy;
m, n, q and r represent, independently of one another, an integer equal to 0 or 1; and
Z is a C—R 13b radical.

4. The composition of claim 2 , wherein:
R 1b is methyl, CN or halogen;
R 2b is S(O) n R 14b ;
R 14b is C 1 -C 6 -alkyl or C 1 -C 6 -haloalkyl;
R 3b is alkyl or haloalkyl;
R 6b is a halogen, C 1 -C 6 -haloalkyl, or C 1 -C 6 -haloalkoxy;
m, n, q and r represent, independently of one another, an integer equal to 0 or 1; and
Z is a C—R 13b radical.

5. The composition of claim 1 or 2 , wherein the veterinarily acceptable carrier comprises acetone, acetonitrile, benzyl alcohol, ethanol, isopropanol, diisobutyl adipate, diisopropyl adipate, butyl diglycol, dipropylene glycol n-butyl ether, ethylene glycol monoethyl ether, ethylene glycol monomethyl ether, dipropylene glycol monomethyl ether, liquid polyoxyethylene glycols, propylene glycol monomethyl ether, propylene glycol monoethyl ether, 2-pyrrolidone, N-methylpyrrolidone, diethylene glycol monoethyl ether, triacetin, butyl acetate, octyl acetate, propylene carbonate, butylene carbonate, dimethyl sulfoxide, an amide, dimethylformamide, dimethylacetamide, or any combination thereof.

6. The composition of claim 1 or 2 , wherein the veterinarily acceptable carrier comprises aryl ethers, alkoxybenzene compounds; aliphatic carboxylic acid esters, aromatic carboxylic acid esters, aliphatic ketones, cyclic ketones, or mixtures thereof.

7. The composition of claim 1 or 2 , wherein the veterinarily acceptable carrier comprises methoxybenzene, butyl acetate, benzyl acetate, methyl isobutyl ketone, ethyl benzoate, benzyl benzoate, octyl acetate, or mixtures thereof.

8. The composition of claim 1 or 2 , wherein the veterinarily acceptable carrier comprises an aprotic solvent with a dielectric constant of about 2 to about 30.

9. The composition of claim 8 , wherein the at least one aprotic solvent(s) with a dielectric constant of about 2 to about 30 is a C 1 -C 10 carboxylic acid ester, a phenyl carboxylic acid ester, a carboxylic acid benzyl ester, a benzoic acid C 1 -C 4 alkyl ester, a C 1 -C 6 saturated aliphatic ketone, or a mixture thereof.

10. A composition for the treatment and prevention of a parasitic infestation in an animal comprising the 1-arylpyrazole compound fipronil, the substituted imidazole compound 1H-imidazole, 2-(2,3-dihydro-4-methyl-1H-inden-1-yl); at least one veterinarily acceptable carrier, and optionally a crystallization inhibitor.

11. A method for the treatment or prevention of a parasitic infestation in an animal comprising administering an effective amount of the composition of claim 1 or 2 to the animal in need thereof.

12. The method of claim 11 , wherein the 1-arylpyrazole compound(s) and the substituted imidazole compound(s) are administered simultaneously.

13. The composition of claim 11 , wherein the veterinarily acceptable carrier comprises acetone, acetonitrile, benzyl alcohol, ethanol, isopropanol, diisobutyl adipate, diisopropyl adipate, butyl diglycol, dipropylene glycol n-butyl ether, ethylene glycol monoethyl ether, ethylene glycol monomethyl ether, dipropylene glycol monomethyl ether, liquid polyoxyethylene glycols, propylene glycol monomethyl ether, propylene glycol monoethyl ether, 2-pyrrolidone, N-methylpyrrolidone, diethylene glycol monoethyl ether, triacetin, butyl acetate, octyl acetate, propylene carbonate, butylene carbonate, dimethyl sulfoxide, an amide, dimethylformamide, dimethylacetamide, or any combination thereof.

14. The composition of claim 2 , wherein the veterinarily acceptable carrier comprises aryl ethers, alkoxybenzene compounds; aliphatic carboxylic acid esters, aromatic carboxylic acid esters, aliphatic ketones, cyclic ketones, or mixtures thereof.

15. The composition of claim 2 , wherein the veterinarily acceptable carrier comprises methoxybenzene, butyl acetate, benzyl acetate, methyl isobutyl ketone, ethyl benzoate, benzyl benzoate, octyl acetate, or mixtures thereof.

16. The composition of claim 2 , wh

Assignees

• Merial Ltd
• Merial Inc

Inventors

• Meng Charles Q

Classifications

• A61P33/14

  Ectoparasiticides, e.g. scabicides · CPC title

• C07D233/58

  with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms · CPC title

• A01N47/02 Primary

  the carbon atom having no bond to a nitrogen atom · CPC title

• A61K31/4164

  1,3-Diazoles · CPC title

• A01N43/50

  1,3-Diazoles; Hydrogenated 1,3-diazoles · CPC title